Key Takeaways
- Competitor disruption is a tailwind: A fire at a peer’s plant has driven a “good quantum” of incremental business and some pricing improvement, factored into forward guidance.
- Unit 3 Phase 1 is imminent: The 2,400 MTPA premium excipient plant (CCS-led) commissions in Oct/Nov 2025, targeting a 25% PAT margin and ~60% first-year utilization.
- A multi-year capacity build is underway: Phase 2 adds 12,000 MTPA of MCC by July 2026, taking total capacity to 24,000 MTPA; management targets a 20–22% blended EBITDA margin once Phase 2 ramps.
- A marquee global customer win validates the platform: After a 3–4 year approval process, a “renowned” MNC will start receiving “multiple 1,000 tons” of MCC, de-risking the Phase 2 ramp.
- What to watch next quarter: The pace of Phase 1 commercialization and trial runs, any further quantification of the competitor-driven order uplift, and whether debtor days begin to rationalize as new MNC relationships mature.
The Sigachi Tailwind
- Demand shift: A fire incident at a competitor’s plant has taken industry capacity offline, leading to increased inquiries and a “good quantum” of business orders flowing to Accent Microcell globally.
- Pricing benefit: Management confirmed “some pricing improvement” has been observed due to the event, though it declined to quantify the specific realization uplift.
- Duration unknown: Management declined to comment on how long the competitor’s plant will take to recover, calling it a matter of company policy, so the tailwind’s persistence is unquantified.
- Order book visibility: The company holds 4–5 months of business on hand, providing near-term confidence in converting the inquiry surge into revenue.
Ghanshyam Patel: “We are having almost 5 to 6 months. We have order on hands. So we are. Know any. There is any threat about this. Unique 3 phase one, and even phase two's order and business.”
Unit 3: The Margin Transformation Thesis
Phase 1: Premium excipients (CCS-led)
- Product and scale: 2,400 MTPA capacity focused on CCS (~70% of output), with CMC and SSG at ~15% each. CCS commands a 3.5x price premium over MCC because it functions as a rapid disintegrant with lower volume usage, not a bulking agent.
- Timeline: Assembly and installation are already in place; commercial production is expected by end-October or the first few weeks of November 2025, with 10–20 days of trial runs thereafter.
- Revenue and margin: Management guided ₹70 crores in revenue from Phase 1 in FY26, read with the partial-year commercialization. Standalone PAT margin for Unit 3 is guided at 25%, driven by the CCS-heavy mix.
- Ramp-up: ~60% capacity utilization is expected in the first year, with customer audits and stability approvals to be completed within that timeline.
Phase 2: MCC scale-up
- Product and scale: 12,000 MTPA of additional MCC capacity, bringing total company capacity to 24,000 MTPA. Capex is ₹55–60 crores (excluding land).
- Timeline: Construction has just started; trial runs are expected from July 2026, with full ramp-up including customer audits by August 2026.
- Utilization: For the financial year Phase 2 comes on stream, capacity utilization is expected around 50–55% over 9 months.
- Traded volume displacement: Phase 2 will drastically reduce traded volumes (currently 15% of revenue at 5–7% PAT margin), replacing them with own-manufactured volumes. Phase 1 will not have this effect.
Blended margin target
- EBITDA target: 20–22% at the blended level, to be achieved gradually within the next couple of years, once Phase 2 is fully operationalized or reaches 70% capacity.
- PAT target: 20–22% PAT margin on the full 24,000 MTPA capacity, subject to full utilization and overhead distribution.
- No margin compression feared: Management does not foresee a decrease in PAT levels for MCC despite new capacity additions, citing focus on export markets and overhead distribution.
Ghanshyam Patel: “Definitely, it is prudent enough to assume the PAT levels of 25% from CCS, that is, that is the basic difference between MCC and premium range of product.”
The Marquee Customer Win
- The win: After a 3–4 year approval exercise, Accent received final confirmation to start supplying microcrystalline cellulose to a “renowned and well-established multinational company globally.”
- Scale: Supply is expected in “multiple 1,000 tons” over the next couple of years, representing a material volume commitment.
- Strategic significance: In highly regulated markets, once a company registers under an NDA, business becomes very long-term and sticky, creating a durable revenue stream.
- Competitive context: Major global competitors are Rocket (US), GRS (Germany), and Ming Thai (Taiwan); customers have switched suppliers in the last 5 years due to price, quality, or supply challenges, so this win is a validation of Accent’s proposition.
- Details withheld: Management declined to reveal the customer’s name, stating “enough was declared” and that peers are also listening.
Ghanshyam Patel: “I just wanted to share the good news from the accent side about the name about the company. Actually, I just don't want to reveal the name of the company, but after you can see 3 to 4 years of approval exercise, we have just received the final confirmation about the business just to start up, and the product would be microsterized cellulose, and that would be renowned and well established multinational company globally.”
Product Portfolio & Technology Shift
- New in-house products: The R&D team has developed four new premium products: SMCC, cellulose powder, MCC spheres, and co-processed MCC, expanding the portfolio from 3–4 to 12–15 products.
- Revenue contribution: 15% of FY25 revenue already came from premium products (CCS, SMCC, spheres, co-processed MCC), sold from existing units.
- End-market expansion: New products target the same pharma customers as MCC but with better flow ability and functionality, plus new segments including tobacco and cosmetics.
- Piranha upgrade under consideration: Management is evaluating upgrading the Piranha facility to spray-dry technology as part of Phase 2, which would narrow the margin gap between the domestic-focused Piranha unit (non-spray-dry, lower margin) and the export-focused Rich unit (spray-dry, ~90% of profits).
- No dumping risk: Management stated there is no fear of dumping in MCC or premium range products from China or other large economies.
Financial Health & Working Capital
- Debtor days pressure: Debtor days rose from 70–80 to over 100 because the company started targeting Indian MNCs and offered longer payment terms to gain a competitive edge; this has been ongoing for 2 years as process validation and stability testing for new MNC customers takes 2–3 years.
- Rationalization expected: Once new MNCs are on-boarded, debtor days should rationalize, though management gave no specific target number, stating “finances will speak for itself.”
- Export mix clarification: Export turnover for FY25 was 61%, not 53% as shown in the presentation, because certain merchant export portions are treated as exports in financial results. The increase in debtor days should be read with a percentage decrease in export sales.
- Inventory levels: Expected to be in line with last reported numbers for FY26; management called it premature to comment on whether new capacities would spike inventory days.
- Debt and leverage: Nominal debt may be considered for working capital requirements of Phase 1; leveraging the company post-commercialization of both units is under consideration.
- Related party transaction: Immovable property worth ₹6 crores was purchased from 3–4 promoters adjacent to the Piranha plant for inventory storage and warehouse construction, at arm’s length price. Management called it a one-off event and does not foresee such transactions in future, but declined to commit to RPT going to zero, calling that “very, very optimistic.”
Ghanshyam Patel: “About, when it comes to RPT stating it to be 0 will be very, very optimistic. So we'll prefer not to comment to it.”
Market Structure & Competitive Position
- Industry growth: Management expects the industry MCC CAGR to increase by 1–1.5% to ~7–8% due to positive market impact from the competitor disruption.
- Domestic demand: Growing “on a similar lens” to global demand at 5–7%, though no specific domestic growth figure was provided.
- Export vs domestic strategy: Incremental capacity will target a 70% export, 30% domestic mix, but management is deliberately expanding its domestic customer base among Indian MNCs to diversify and reduce export dependency amid geopolitical and tariff risks.
- Raw material security: 95% of major raw material (different grades of pulp) is imported from the USA, South Africa, Sweden, and Indonesia; no supply chain constraints or negative impact from geopolitical tensions are expected.
- Gross margin differential vs peers: Differences across MCC players (Sigachi ~50%, Patel ~30%, Accent ~40%) are due to different product baskets, export vs domestic mix, and usage of superior grade raw material.
- Long-term vs spot contracts: Long-term contracts (10–15% of business) have price fixed on 6-month, monthly, or yearly bases with quantity assurance from distributors; cost increases are communicated to partners per agreement terms. Spot contracts have no price locking.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue CAGR | 15–20% over 3–5 years; near-term growth can be higher | 3–5 year horizon |
| Blended EBITDA margin | 20–22% | Within next couple of years, once Phase 2 is fully operationalized or at 70% capacity |
| Unit 3 Phase 1 commercialization | Commercial production begins | End of October / first week of November 2025 |
| Unit 3 Phase 1 FY26 revenue | ₹70 crores (partial year) | FY26 |
| Unit 3 Phase 1 first-year utilization | ~60% | First year post-commercialization |
| Unit 3 Phase 1 standalone PAT margin | 25% | From commercialization |
| Unit 3 Phase 2 trial runs | Trial runs commence | July 2026 |
| Unit 3 Phase 2 capex | ₹55–60 crores (excluding land) | Construction just started |
| Unit 3 Phase 2 first-year utilization | 50–55% over 9 months | Financial year of commissioning |
| Full-capacity blended PAT margin | 20–22% on 24,000 MTPA | Subject to full utilization and overhead distribution |
| New global customer supply | “Multiple 1,000 tons” of MCC | Over next couple of years |
| Debtor days rationalization | Expected to rationalize | Once new MNCs are on-boarded |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue (FY25) | ₹265 cr, near-peak capacity utilization |
| EBITDA margin (FY25) | ~16%, with target of 20–22% in next couple of years |
| PAT margin target (Phase 1, Unit 3) | 25% for CCS product |
| Weighted average PAT margin target (full 24,000 MT capacity) | 20–22% |
| Company-level revenue CAGR target | 15–20% for next 3–5 years |
| Industry MCC CAGR | 5–6%, expected to increase by 1–1.5% |
| Current total capacity | 9,600 metric tons per annum |
| Unit 3 Phase 1 capacity (premium excipients) | 2,400 metric tons per annum, commissioning by Oct–Nov 2025 |
| Unit 3 Phase 2 capacity (MCC) | 12,000 metric tons per annum, commissioning by Jul 2026 |
| Total capacity post all expansions | 24,000 metric tons per annum |
| Export mix | 65% of total turnover |
| US exposure | 4–5% of total turnover |
| Order book | 5–6 months of orders on hand for Unit 3 Phase 1 and Phase 2 |
| Long-term contracts | 10–15% of turnover, rest are open or spot contracts |
| Debtor days | Over 100 days, increased from 70–80 range in last 2 years |
| Global MCC market size | 250,000 metric tons per annum |
| Indian MCC market size | 50,000 metric tons per annum |
| Total capex for Unit 3 (Phase 1 + Phase 2, excluding land) | ₹105–110 cr |
| Rights issue amount | ~₹40 cr |
| Phase 2 capex | ₹55–60 cr, excluding land |
| FY25 traded volumes | 15% of total, own manufactured 85% |
| PAT margin on traded goods | 5–7% |
| Raw material inventory | ~2 months; finished goods inventory ~1 month |
| CCS price vs MCC | ~3.5 times MCC price |
| MCC export price | ~₹230 per kg; domestic ~₹180 per kg |
| Incremental realization from new premium products | 5–7% increase in sales of finished goods |
| Phase 1 expected utilization in first year | ~60% |
| Phase 2 expected utilization in first year | 50–55% for that financial year (9 months) |
| FY25 domestic revenue | ~₹120 cr |
| FY25 domestic profit | ~₹2 cr, 2% margin |
| Export geographic split | North & South America 55%, Asia 30–35%, Europe 8–10%, Australia 5% |
| FY28 full-ramp top line potential (all 3 units, current prices) | ~₹700 cr (per an analyst's math) |